Modes of resistance to anti-angiogenic therapy - Wikidata - awgldk - TriplyDB

Modes of resistance to anti-angiogenic therapy

Modes of resistance to anti-angiogenic therapy

http://www.wikidata.org/entity/Q24608005

about

The notch ligand JAGGED1 as a target for anti-tumor therapy Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis MicroRNA-mediated regulation of the angiogenic switch Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis Cancer systems biology: a network modeling perspective Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?Tumor refractoriness to anti-VEGF therapy Hepatocellular carcinoma: Where are we?Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Potential of Induced Metabolic Bioluminescence Imaging to Uncover Metabolic Effects of Antiangiogenic Therapy in Tumors Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors Pharmacologic resistance in colorectal cancer: a review Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker Endothelial Transdifferentiation of Tumor Cells Triggered by the Twist1-Jagged1-KLF4 Axis: Relationship between Cancer Stemness and Angiogenesis Sequence of treatment in locally advanced and metastatic renal cell carcinoma Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer Cancer stem cell targeted therapy: progress amid controversies.Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization CRISPR-Cas9: A Revolutionary Tool for Cancer Modelling Progress toward overcoming hypoxia-induced resistance to solid tumor therapy Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Potential function of miRNAs in herpetic stromal keratitis Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme Targeting angiogenesis in gynecologic cancers Tumor cell vasculogenic mimicry: from controversy to therapeutic promise Circulating glioma biomarkers Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells

P2860

Q21129294-C431497F-04B1-49DF-9A02-CFC572B0BB2C Q21132534-63F2F946-C730-4DED-BAD2-478682C49C31 Q21135545-5148BF14-FB9A-46EF-87AC-94359932A6B2 Q21183974-66D8DF76-C0E1-421D-989F-0D393D402F80 Q24202199-74A33210-4025-4F85-A09F-90F385C868DD Q24293027-88FE85C2-730D-4703-BE96-315A7FF0E420 Q24296427-5EB49A13-96F9-431D-AE53-735CA20CB259 Q24298455-8B7DA5A6-CAC9-4327-B297-6B1708410A15 Q24564890-94207706-ECBE-4C06-87EA-75ED9F9041DF Q24604279-0B36D374-4991-4759-9A90-230468DA2014 Q24608039-7DC35597-2F09-4773-8CA5-BF08E50221BF Q24613766-9871C7BD-0A6A-4239-9BAB-FEDA8BDB509C Q24616631-F8B59536-04AB-4124-9763-C7313CD1CC54 Q24634064-495F5042-3E04-4A29-9C87-5ED6D3B749B6 Q24650086-853A386E-6B62-4815-B338-31568EC5B719 Q26739760-9A6A01EA-9884-4D0A-A608-A85140532082 Q26747678-DA99CB9A-7B72-4A6D-AFE8-F204C6D11661 Q26765182-011443D1-6F78-45CF-B4E3-C0FF4425A0D6 Q26766240-B683FB06-C94B-4A93-B813-ADA601E7AA22 Q26766351-18A5C632-BE74-4D5A-A2AA-83B8B21B2283 Q26766689-983127A1-A8B0-4A0D-B6CC-623C09A2182D Q26768267-38B0E9B5-3527-4F25-8B20-39BFCC475F98 Q26769850-55E9F652-E00D-4B5A-8A5D-1FA823F9DF6E Q26771513-D86C3D21-86FC-461C-99E1-5E8350A42166 Q26773015-DBB79C96-938C-450B-A3F9-0D92B2B9744E Q26773653-AD50EBB7-ACD6-498F-B407-3EEF4471FFFD Q26778344-07987D4C-EA46-4682-8664-1C1D009B50D6 Q26779248-58DBF58A-4F25-412D-B303-53FEB3BF8D31 Q26779931-267E4C83-5B0E-4B46-A792-970FDC9A9A0D Q26781833-950229E7-F265-4CB2-AF99-AE454B3FACBE Q26782773-95552542-CEF6-4FB4-84D3-2223527C098A Q26796405-17B097E7-CAC6-4ADF-9158-E7E5957994FA Q26801289-8E8BDFC2-7110-4D2F-AC06-B83145E3F866 Q26821959-E2ABFB68-49FE-4B54-98A3-899AA7C65C32 Q26823201-EC3CFF44-B13D-4CA4-9889-F2E598EF3435 Q26824557-9AD5DBC3-E008-49C2-8ECF-DB0FCD3DCF6E Q26824766-8D794335-EC1A-432B-84B9-606BF864FB52 Q26829921-F743ACD4-B100-41B3-80E7-C388FE1CAC3C Q26830329-51297B63-94B4-4CA8-A6E0-445F1E146A96 Q26852287-EF0B87A2-F7E2-4526-B024-5EC731E41D57

P2860

Modes of resistance to anti-angiogenic therapy

http://www.wikidata.org/entity/Q24608005

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Modes of resistance to anti-angiogenic therapy

@ast

Modes of resistance to anti-angiogenic therapy

@en

Modes of resistance to anti-angiogenic therapy

@nl

type

label

Modes of resistance to anti-angiogenic therapy

@ast

Modes of resistance to anti-angiogenic therapy

@en

Modes of resistance to anti-angiogenic therapy

@nl

prefLabel

Modes of resistance to anti-angiogenic therapy

@ast

Modes of resistance to anti-angiogenic therapy

@en

Modes of resistance to anti-angiogenic therapy

@nl

P1433

Q24608005-E3F74B9D-3485-4381-A579-11A4A96472BF

P1476

Q24608005-5FEC0531-9526-4F3A-8609-614280F2623A

P2093

Q24608005-C0A087E5-4EC0-424C-A65E-C9AEBF309DDC

Q24608005-D57FF97D-A73B-4351-96E4-F57D40431870

P2860

Q24608005-018DB4E1-921C-43B8-9C7D-4669934AA656

Q24608005-01E68ECE-5EE5-4ED7-A8B8-C80BDF9C6776

Q24608005-05BDED0A-87DF-43CA-9850-8EEFAB108BDA

Q24608005-05D16006-0CD3-4B99-948B-23CF0AD1BDF8

Q24608005-0733CE91-497A-43A3-B623-257EEE1971E3

Q24608005-0DE2DCF9-9E12-44BA-89F4-23CFFDFCDED9

Q24608005-0FC774E5-ED3A-45A9-8B23-C38DEB862F82

Q24608005-117D7B02-3EFE-4464-AC02-71E546617BA4

Q24608005-11FAD18C-4FA1-4B49-98EF-3E462597CB6B

Q24608005-15F81DE8-F07A-4369-B829-BC2419AAEDE5

P2888

Q24608005-63083879-36AD-4A8F-AC99-F67AC35416AD

P304

Q24608005-E46A1BEF-F21B-44B0-A356-2CC351E4D678

P31

Q24608005-B80D15C3-4045-45CD-8FB9-032686F6507F

P3181

Q24608005-3BCE8600-0EC8-445B-831F-EE4F780C85E8

P356

Q24608005-63E5C5A0-9F3F-4509-88E3-835A4BDC6717

P407

Q24608005-8387F78B-D4E9-4643-A598-275B496C3BE8

P433

Q24608005-96697779-558C-4AED-A027-DB49B64A00B9

P478

Q24608005-DF9D8CF1-75D1-49C5-96A4-D79F774CBFFD

P577

Q24608005-1512DC4E-4DA0-4F69-BAE5-4E4459FFE38A

P5875

Q24608005-D5B3E226-8FB0-48AA-A408-1F590E2942FD

P6179

Q24608005-C65CD568-3DF8-40F3-B518-791284E31897

P698

Q24608005-33BF5B87-BDAC-4981-BA14-3C69BC6260C1

P932

Q24608005-A03FB22A-9015-424B-BEF8-4B587A6DCF29

P3181

P356

P1433

Nature Reviews Cancer

P1476

Modes of resistance to anti-angiogenic therapy

@en

P2093

Douglas Hanahan

http://www.w3.org/2001/XMLSchema#string

Gabriele Bergers

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

The role of pericytes in blood-vessel formation and maintenance

Genetic alterations in pancreatic carcinoma

Targeting HIF-1 for cancer therapy

Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion

A quantitative analysis of kinase inhibitor selectivity

Isolation of putative progenitor endothelial cells for angiogenesis

Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting

P2888

P304

592-603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

604359

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRC2442

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51424400

http://www.w3.org/2001/XMLSchema#string

P6179

1013847179

http://www.w3.org/2001/XMLSchema#string

P698

18650835

http://www.w3.org/2001/XMLSchema#string

P932

2874834

http://www.w3.org/2001/XMLSchema#string